Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + FOLFOXIRI + Radiotherapy vs CAPOX + Radiotherapy for pMMR Locally Advanced Low Rectal Cancer
NCT07277842Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab in rectal adenocarcinoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Event-Free Survival at 3 years. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07277842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277842.